期刊文献+
共找到180篇文章
< 1 2 9 >
每页显示 20 50 100
Hydroxyurea-related ileocecal region ulcers as a rare complication:A case report
1
作者 Wen-Jin Yuan Yi-Juan Zheng +4 位作者 Bing-Rong Zhang Yi-Jie Lin You Li Yan-Yan Qiu Xue-Ping Yu 《World Journal of Clinical Cases》 SCIE 2025年第6期24-29,共6页
BACKGROUND Hydroxyurea,an antimetabolite,is frequently prescribed for various hemato-logical disorders,and its common side effects include gastrointestinal problems,cutaneous or mucosal lesions and pyrexia/fever.CASE ... BACKGROUND Hydroxyurea,an antimetabolite,is frequently prescribed for various hemato-logical disorders,and its common side effects include gastrointestinal problems,cutaneous or mucosal lesions and pyrexia/fever.CASE SUMMARY This study reports the case of a 67-year-old woman who developed recurrent abdominal pain after 10 years of continuous hydroxyurea therapy for primary thrombocythemia.Colonoscopy revealed an ileocecal ulcer.After discontinuing hydroxyurea therapy for 6 months,follow-up colonoscopy showed a significant reduction in the ulceration.CONCLUSION We consider cecal ulcers as a rare complication of hydroxyurea therapy which typically resolves upon stopping the drug. 展开更多
关键词 hydroxyurea ULCER Abdominal pain THROMBOCYTHEMIA COLONOSCOPY Case report
暂未订购
Influence of Hemoglobin S Haplotypes on the Responses to Hydroxyurea Treatment in Children with Sickle Cell Disease in Abidjan, Côte d’Ivoire
2
作者 Mireille Aye-Yayo Vincent Yapo +5 位作者 Boidy Kouakou Missa Louis Adjé Adia Eusèbe Adjambri Ebah Hermance Kassi Taïratou Kamagate Duni Sawadogo 《Open Journal of Genetics》 CAS 2024年第1期1-12,共12页
Background: In Côte d’Ivoire so far, the circulating haplotypes have been inferred on the phenotypic profiling of SCD patients. The impact of the circulating haplotypes on the use of Hydroxyurea has not been ass... Background: In Côte d’Ivoire so far, the circulating haplotypes have been inferred on the phenotypic profiling of SCD patients. The impact of the circulating haplotypes on the use of Hydroxyurea has not been assessed yet. Therefore the objective of this study is to identify in Abidjan the HbS haplotypes that modulate HU treatment responses. Methods: In a cross-sectional descriptive and analytical study, children aged 5 to 15 years with SCD, and carrying the hemoglobin phenotypes SSFA2 and SFA2, were recruited into a HU treatment cohort. Various parameters on the haplotypes and the outcomes of the treatment were analyzed. Results: Thirty nine children with SCD were included. The phenotypic profile of the cohort was 86.6% of SSFA2 and 15.4% of SFA2. Three haplotypes were found, the Benin haplotype, the Senegal haplotype, and an atypical one. The participants belonged to three genotypes, Benin/atypical (64.1%), Benin/Senegal (33.3%) and Senegal/Senegal (2.6%). Overall, HU treatment was successful in all haplotypes with 12 out of 39 patients failing treatment after 12 months in the Benin haplotype group. The association between HU treatment success and the Benin haplotype was found in terms of the decrease in the number of white blood cells and the students missing class. Conclusion: The study revealed that inferring haplotype based on the phenotypic profile could be inaccurate. The proportion of atypical haplotype that were not previously described in Côte d’Ivoire was high. All the haplotypes seemed to be associated with HU treatment success but some patients with Benin haplotype did not respond well. 展开更多
关键词 Sickle Cell Disease CHILDREN HAPLOTYPE hydroxyurea Côte d’Ivoire
暂未订购
Review on Hydroxyurea Usage in Young Children with Sickle Cell Disease: Examining Hemoglobin Induction, Potential Benefits, Responses, Safety, and Effectiveness
3
作者 Maiko Charles Mkwambe Youping Deng Dongchi Zhao 《International Journal of Clinical Medicine》 CAS 2024年第1期1-18,共18页
Sickle cell disease (SCD) is a prevalent condition, particularly in the countries of sub-Saharan Africa, where the presence of specific genes associated with Malaria contributes to its high prevalence. Patients with s... Sickle cell disease (SCD) is a prevalent condition, particularly in the countries of sub-Saharan Africa, where the presence of specific genes associated with Malaria contributes to its high prevalence. Patients with sickle cell disease frequently experience painful episodes necessitating hospitalization, and their hemoglobin levels are typically lower than those of the general population. There are different treatment options available to manage complications, such as transfusing blood, hydroxyurea, and strong anti-pains. However, with all these treatments, patients still commonly experience pain crises and suffer from organ damage. Hydroxyurea, the sole approved medication for sickle cell anemia in developed and developing countries, is widely used in children despite being primarily indicated for adults. Multiple studies have demonstrated the efficacy of hydroxyurea in inducing HbF production in young children with SCD. Elevated HbF levels have been associated with improved clinical outcomes, including a reduction in vaso-occlusive crises, acute chest syndrome, and the need for blood transfusions. Furthermore, increased HbF levels have been shown to ameliorate disease-related organ damage, such as pulmonary hypertension and sickle cell retinopathy. The response to hydroxyurea treatment in young children with SCD is variable. Some patients achieve substantial increases in HbF levels and experience significant clinical benefits, while others may have a more modest response. Factors influencing the response include baseline HbF levels, genetic modifiers, treatment adherence, and dose optimization. Safety is a crucial consideration when using hydroxyurea in young children. Studies have shown that hydroxyurea is generally well-tolerated, with the most common adverse effects being myelosuppression, gastrointestinal symptoms, and dermatological manifestations. However,long-term effects and potential risks, such as renal dysfunction and reproductive impacts, require further investigation. The effectiveness of hydroxyurea in young children with SCD has been demonstrated in various clinical trials and observational studies. These studies have shown a significant reduction in disease-related complications and improved quality of life. However, optimal dosing, treatment duration, and long-term outcomes are still areas of ongoing research. This review focuses on recent studies investigating the benefits, effectiveness, responses, and safety of hydroxyurea in pediatric individuals diagnosed with sickle cell disease. 展开更多
关键词 EFFECTIVENESS hydroxyurea Sickle Cell Disease Sickle Cell Anemia Minimally Effective Dose Maximum Tolerated Dose
暂未订购
Cistanche deserticola decoction alleviates the testicular toxicity induced by hydroxyurea in male mice 被引量:5
4
作者 Li Gu Wen-Ting Xiong Chao Wang Hong-Xia Sun Guo-Fu Li Xin Liu 《Asian Journal of Andrology》 SCIE CAS CSCD 2013年第6期838-840,I0011,共4页
This study aimed to evaluate testicular toxicity induced by hydroxyurea (HU) and the possible counteracting effect of an aqueous extract of Cistanche deserticola (CD). HU is an antineoplastic drug that has potenti... This study aimed to evaluate testicular toxicity induced by hydroxyurea (HU) and the possible counteracting effect of an aqueous extract of Cistanche deserticola (CD). HU is an antineoplastic drug that has potential reproductive toxicity, and Herba Cistanche has been used as a tonic for the reproductive system for thousands of years. Sixty mice were randomly divided into five groups. Except mice in normal group, the rest received HU (400 mg kg^-1 body weight) intragastrically. Meanwhile, mice in normal and HU control groups received purified water, and the rest received intragastrically three doses of CD decoctions (1.5, 3.0 and 6.0 g crude drug kg^-1 body weight, respectively) daily for 4 weeks. Severe testes lesions were observed, testes weight (P〈0.01) and serum luteinising hormone levels (P〈0.0 1) were also decreased significantly, in the HU groups. Three doses of CD decoctions alleviated the spermatogenetic cell degeneration induced by HU and modulated the serum sex hormones levels to some extent. 展开更多
关键词 Cistanche deserticola HORMONES hydroxyurea semin iferous tubule
暂未订购
The apoptosis of HEL cells induced by hydroxyurea 被引量:2
5
作者 GUI CHANG YUN CHU JIANG +1 位作者 HENG YUE XIE RUO LAN QIAN(Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai 200031) 《Cell Research》 SCIE CAS CSCD 1997年第1期91-97,共7页
Hydroxyurea has been used to synchronize cultured cells to S-phase and used to treat patients with sicklecell anemia. Recently, we found that hydroxyurea can induce the apoptosis of HEL (human erythroleukemia) cells.T... Hydroxyurea has been used to synchronize cultured cells to S-phase and used to treat patients with sicklecell anemia. Recently, we found that hydroxyurea can induce the apoptosis of HEL (human erythroleukemia) cells.The induced HEL cells showed ultrastructurally chromatin condensation with regular crescents at the nuclear edges and apoptotic bodies. However, the cells of K562, another human erythroleukemia cell line, did not show such morphological changes. Under fluoroscope, the HEL cells after induction often displayed a clear reduction in nuclear diameter and nuclear chromatin cleavage and condensation and the presence of nuclear ring and apoptotic bodies. Analysis with flow cytometry showed that the percentage of apoptotic cells is about 30-40% after HEL cells were induced by hydroxyurea for 3 days. DNA ladder can be observed by electrophoretic analysis. 展开更多
关键词 HEL cells hydroxyurea APOPTOSIS
暂未订购
Function of GATA transcription factors in hydroxyurea-induced HEL cells 被引量:2
6
作者 ZhanSB HeQY 《Cell Research》 SCIE CAS CSCD 2001年第4期301-310,共10页
HEL cells, a human erythroleukemia cell line, mainly express the fetal (r)globin gene and trace amount of the embryonic (E)globin gene, but not adult (B) globin gene. Here we show that hydroxyurea (HU) can induce HEL ... HEL cells, a human erythroleukemia cell line, mainly express the fetal (r)globin gene and trace amount of the embryonic (E)globin gene, but not adult (B) globin gene. Here we show that hydroxyurea (HU) can induce HEL cells to express adult (B) globin gene and lead these cells to terminal differentiation. Results showed in Gel mobility shift assays that GATA factors could specifically bind to the regulatory elements of human B- globin gene, including the proximal regulatory element (the B- promoter) and the distal regulatory elements (the DNase I hypersensitive sites in the LCR, HS2-HS4 core sequences). However, the DNA binding patterns of GATA factors were quite different between HU-induced and uninduced HEL cells. Western-blot analysis of nuclear extracts from both the uninduced and HU- induced HEL cells revealed that the level of GATA-2 transcription factor decreased, whereas the level of GATA-1 transcription factor increased following the time of hydroxyurea induction. Furthermore, using RT-PCR analysis the expression of human B-globin gene in HU-induced HEL cells could be blocked again when HEL cells were incubated in the presence of antisense oligonucleotides for hGATA-1, suggesting that the upregulation of hGATA-1 transcription factor might be critical for the expression of human β- globin gene in HU-induced HEL cells. 展开更多
关键词 GATA transcription factors human β-gobin gene HEL cells hydroxyurea.
暂未订购
INDUCTION OF C-MYC GENE AMPLIFICATION BY HYDROXYUREA AND ITS INHIBITION BY HOMOHARRINGTONINE 被引量:1
7
作者 刘杰 杨胜利 胥彬 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1989年第1期26-30,共5页
Induction of c-myc gene amplification in L1210 cells by hydroxyurea and its inhibition by homohar-ringtonine were investigated using the DNA-DNA molecular hybridization technique. When the cells were treated with hydr... Induction of c-myc gene amplification in L1210 cells by hydroxyurea and its inhibition by homohar-ringtonine were investigated using the DNA-DNA molecular hybridization technique. When the cells were treated with hydroxyurea 1.0 mM for 16 hours, and incubated a further 16 hours in a drug-free medium, the c-myc gene amplified 23.5-fold. If homohar-ringtonine 50 μM was used at the same time as hydroxyurea, gene amplification did not occur. Cycloheximide, an inhibitor of protein biosynthesis, produced a similar effect. Our results indicated that a (or some) protein factor(s) might be involved in gene amplification. Detailed analysis showed that the synthesis of this protein factor(s) started 4 hours before the initiation of the S phase but did not continue in the S phase. It was also found that this protein factor(s) was very labile and began to degrade 2 hours after its appearance. 展开更多
关键词 gene INDUCTION OF C-MYC GENE AMPLIFICATION BY hydroxyurea AND ITS INHIBITION BY HOMOHARRINGTONINE DNA
暂未订购
Hydroxyurea-induced cutaneous squamous cell carcinoma: A case report
8
作者 Yan Xu Jian Liu 《World Journal of Clinical Cases》 SCIE 2019年第23期4091-4097,共7页
BACKGROUND Hydroxyurea(HU)is a non-alkylating antineoplastic agent that is active in the Sphase of the cell cycle and inhibits the enzyme ribonucleoside reductase.HU is currently used to treat leukemia,sickle cell ane... BACKGROUND Hydroxyurea(HU)is a non-alkylating antineoplastic agent that is active in the Sphase of the cell cycle and inhibits the enzyme ribonucleoside reductase.HU is currently used to treat leukemia,sickle cell anemia,psoriasis,and chronic myeloproliferative disorders.Although HU is easy to use and effective and has high tolerance,there have been numerous reports of cutaneous complications during long-term therapy with HU.CASE SUMMARY We report a 67-year-old woman on long-term HU therapy for primary myelofibrosis who developed concurrent skin lesions during treatment.The first skin lesion appeared on the dorsum of her right hand in 2015.Despite continuous use of HU,her cutaneous changes were neglected.Approximately 3 years ago,she had multiple nodular and keratotic lesions on both hands with sharp margins,branny desquamation,and dotted hyperpigmentation.Furthermore,she developed acutely numerous ulcerative lesions on her hands and legs.Topical wound therapy with dressing changes and parenteral antibiotics was applied for management of the lesions.Most of the wounds healed after HU withdrawal.Lesions on both hands were replaced by scabs.Nevertheless,the wound on her left ankle reached 9 cm×7 cm in size in January 2018.Pathology confirmed welldifferentiated squamous cell carcinoma at the ulcer area.In addition,her left foot was severely affected and radical surgery with a below-the-knee amputation was suggested followed by preventive right groin nodal dissection.CONCLUSION In patients receiving continuous HU therapy,close dermatologic follow-up is critical for the early diagnosis and selection of appropriate treatment for cutaneous lesions. 展开更多
关键词 hydroxyurea SQUAMOUS cell CARCINOMA PRIMARY MYELOFIBROSIS Case report
暂未订购
Gap Junctional Intercellular Communication Increases Cytotoxicity and Reduces Resistance to Hydroxyurea
9
作者 Randall J. Ruch Paul D. Boucher +1 位作者 Brian G. Gentry Donna S. Shewach 《Journal of Cancer Therapy》 2014年第13期1190-1202,共13页
Background: Gap junctions enable small molecules to diffuse between adjacent cells and have been associated with greater cytotoxicity of radiation and anti-cancer drugs. We investigated?whether this gap junctional int... Background: Gap junctions enable small molecules to diffuse between adjacent cells and have been associated with greater cytotoxicity of radiation and anti-cancer drugs. We investigated?whether this gap junctional intercellular communication (GJIC) affected the cytotoxicity of the classic?ribonucleotide reductase (RR) inhibitor and anti-cancer agent, hydroxyurea (HU). Materials and Methods: We used GJIC-proficient and deficient, connexin 43-expressing WB rat liver epithelial cell lines. We compared HU toxicity by crystal violet assay, effects of the drug on deoxynucleotide pools by HPLC, and ability of GJIC to increase toxicity of HU-resistant cells through a bystander effect in co-culture experiments. Results: GJIC-proficient cells were three- to five-fold more sensitive (IC50?0.1 mM) to HU than GJIC-deficient derivatives (IC50?0.3 - 0.5 mM). This sensitivity depended upon GJIC because treatment of GJIC-proficient cells with the GJIC blocker oleamide decreased HU toxicity by approximately 60% - 80% and restoration of GJIC in GJIC-deficient cells by stable transduction of connexin 32-encoding?Gjb1?increased HU toxicity (IC500.1 mM). The effects were not due to connexin expression?per se?or its localization since all cell lines expressed comparable quantities of connexin 43 that was localized to the plasma membrane. Also HU sensitivity was not related to differential effects on nucleotide metabolism in the cells. Thymidine triphosphate levels increased and deoxyadenosine triphosphate levels decreased similarly (15% - 20%) in GJIC-proficient and deficient cells over 24 h of HU treatment. More importantly, when HU-resistant cells were co-cultured with sensitive cells, the resistant cells were killed only when GJIC?was present. Conclusion: The data suggest that GJIC enhances cytotoxicity and decreases resistance?to HU. These results may be important clinically if GJIC can be enhanced in drug-resistant cells. 展开更多
关键词 BYSTANDER Effect Drug RESISTANCE Gap JUNCTIONS hydroxyurea Ribonucleotide REDUCTASE
暂未订购
羟基脲(Hydroxyurea)对细胞周期与珠蛋白基因表达的影响(简报) 被引量:5
10
作者 蒋俶 戴长虹 +4 位作者 谢恒月 陈雅娣 胡炜 龚钟萍 钱若兰 《实验生物学报》 CSCD 1997年第1期109-114,共6页
已有许多证据表明羟基脲能增加镰状细胞贫血及β-地贫病人的胎儿型血红蛋白(HbF)的合成。最近,有人报道羟基脲也能使一些患有β-地贫病人的β-珠蛋白基因表达增加。K562细胞是人红白血病细胞株,它只能表达胚胎型(ε-)与胎儿型(γ-)珠蛋... 已有许多证据表明羟基脲能增加镰状细胞贫血及β-地贫病人的胎儿型血红蛋白(HbF)的合成。最近,有人报道羟基脲也能使一些患有β-地贫病人的β-珠蛋白基因表达增加。K562细胞是人红白血病细胞株,它只能表达胚胎型(ε-)与胎儿型(γ-)珠蛋白基因,而不能表达成年型(β-)珠蛋白基因。因此。 展开更多
关键词 细胞周期 珠蛋白基因 羟基脲 肿瘤
暂未订购
Sickle Crisis Precipitated by Pneumonia: A Diagnostic and Therapeutic Challenge
11
作者 David Fernando Ortiz-Pérez Luisa María Petro-Noriega +8 位作者 Margarita Rosa Burgos-Peña Marlon José Rosado-Mendoza Santiago Sánchez-Rojas Cristina De Jesús Portillo-Monterrosa Daniel de Jesús González-Villarreal Juan Pablo de la Ossa Díaz John Sebastián Osorio-Muñoz Manuel Esteban Ortiz Pérez Ana María García-Suárez 《Journal of Biosciences and Medicines》 2025年第1期255-263,共9页
Sickle cell anemia (SCA) is a prevalent genetic disorder primarily affecting individuals of African descent and populations in malaria-endemic regions, with significant global public health implications. Sickle cell c... Sickle cell anemia (SCA) is a prevalent genetic disorder primarily affecting individuals of African descent and populations in malaria-endemic regions, with significant global public health implications. Sickle cell crises are their most common acute complication, characterized by episodes of intense pain and systemic manifestations that impair quality of life and impose a high healthcare burden. We present the case of a 19-year-old male diagnosed with SCA since the age of two, who developed a sickle cell crisis precipitated by right basal pneumonia. The patient exhibited sudden-onset, cyclic lumbar pain with progressive dyspnea. Initial management included multimodal pain control, volume optimization, and targeted antimicrobial therapy to achieve clinical stabilization. This case underscores the importance of a comprehensive approach to managing sickle cell crises, addressing both symptomatic relief and the prevention and treatment of complications. It also highlights the need for public health strategies promoting early diagnosis, access to disease-modifying therapies such as hydroxyurea, and interdisciplinary follow-up to mitigate the socioeconomic and clinical impact of SCA. 展开更多
关键词 Sickle Cell Anemia Sickle Cell Crisis Pain Management PNEUMONIA hydroxyurea
暂未订购
儿童血小板增多症诊治进展
12
作者 徐雨婷(综述) 胡群(审校) 《中国当代儿科杂志》 北大核心 2025年第2期236-241,共6页
血小板增多症是儿科的常见疾病,包括原发性和继发性两类。继发性常由感染、贫血、缺铁、外伤或手术等引起,一般无严重血栓形成或出血事件发生。原发因素控制后血小板计数多可恢复正常,临床过程及结局良好。原发性由骨髓增生性肿瘤如真... 血小板增多症是儿科的常见疾病,包括原发性和继发性两类。继发性常由感染、贫血、缺铁、外伤或手术等引起,一般无严重血栓形成或出血事件发生。原发因素控制后血小板计数多可恢复正常,临床过程及结局良好。原发性由骨髓增生性肿瘤如真性红细胞增多症、原发性血小板增多症、骨髓纤维化等引起,常伴有造血细胞基因突变。临床表现相较于成人不典型,血栓栓塞及出血事件少见。无症状或症状轻微者一般无需特殊治疗,建议定期监测血小板数值。有血栓形成风险或血小板极度增多者可以考虑使用阿司匹林抗血小板治疗,必要时进行降细胞治疗,但需密切监测药物毒副作用。目前常用的降细胞药物包括羟基脲、干扰素α、阿那格雷等。该文通过介绍儿童血小板增多症的病因及分类、临床表现、诊断及治疗,旨在进一步为临床医师提供治疗决策。 展开更多
关键词 血小板增多症 原发性血小板增多症 血栓栓塞 羟基脲 儿童
暂未订购
羟基脲治疗输血依赖型β-地中海贫血的临床效果及药物经济学评价
13
作者 蒋慧娴 黄天敏 +6 位作者 郭雁翔 颜潇旖 唐甘翎 李静怡 黄肖曼 黄振光 张宏亮 《广西医学》 2025年第4期578-584,共7页
目的评价羟基脲治疗输血依赖型β-地中海贫血的有效性、安全性和经济性。方法采用回顾性研究方法,纳入80例输血依赖型β-地贫患者作为研究对象。其中,羟基脲组(n=40)采用常规输血加用羟基脲治疗,常规治疗组(n=40)采用常规输血治疗,比较... 目的评价羟基脲治疗输血依赖型β-地中海贫血的有效性、安全性和经济性。方法采用回顾性研究方法,纳入80例输血依赖型β-地贫患者作为研究对象。其中,羟基脲组(n=40)采用常规输血加用羟基脲治疗,常规治疗组(n=40)采用常规输血治疗,比较两组的疗效和安全性。构建Markov模型进行成本-效用分析,比较两组的经济性。结果治疗后,羟基脲组的血红蛋白水平高于治疗前及常规治疗组(P<0.05),但两组的治疗总有效率、输血频次及输血量差异无统计学意义(P>0.05),且安全性相似。成本-效用分析结果显示,与常规治疗组相比,羟基脲组的人均增量成本为1559.13元,人均增量效用为0.20质量调整生命年(QALY),增量效果比为7522.47元/QALY,表明当意愿支付值超过7522.4元时,羟基脲具有一定的成本-效用优势。概率敏感性分析显示成本-效用分析结果较为稳定。结论对于输血依赖型β-地中海贫血患者,常规输血治疗加用羟基脲相较于常规治疗方案具有一定的临床优势和成本-效用优势。 展开更多
关键词 Β-地中海贫血 输血依赖型 羟基脲 输血治疗 MARKOV模型 疗效 安全性 成本-效用分析
暂未订购
Treatment of β-Thalassemia With Hydroxyurea (HU)——Effects of HU on Globin Gene Expression 被引量:1
14
作者 黄淑帧 任兆瑞 +5 位作者 陈美珏 许洪平 曾溢滔 G.P.Rodgers 曾凡一 A.N.Schechter 《Science China Chemistry》 SCIE EI CAS 1994年第11期1350-1359,共10页
A newly developed method of RT-PCR/competitive PCR for measuring the relative and ab-solute content of globin mRNAs as well as micro-globin chain biosynthetic assay have been used to study thealterations of globin gen... A newly developed method of RT-PCR/competitive PCR for measuring the relative and ab-solute content of globin mRNAs as well as micro-globin chain biosynthetic assay have been used to study thealterations of globin gene expressions in the patients with β-thalassemia pre-and post-hydroxyurea(HU)treatment.It was found for the first time that HU had the effect of enhancing β-globin gene expression insome patients.Two cases with β-thalassemia who were subjected to HU treatment for over two years showeda marked increase in β-globin mRNA level and β-globin chain synthesis,resulting in more effective erythro-poiesis and the alleviation of clinical symptoms. 展开更多
关键词 Β-THALASSEMIA GLOBIN GENE EXPRESSION hydroxyurea
原文传递
费城染色体阴性骨髓增殖性肿瘤基因突变与治疗进展
15
作者 周泓羽 陈林 《医学综述》 2025年第6期672-679,共8页
骨髓增殖性肿瘤(MPN)是髓系细胞过度增生引起的血液系统疾病。大多数MPN患者中可检出Janus激酶(JAK)2、血小板生成素受体基因及钙网蛋白基因突变,未检出上述3种基因突变MPN患者被定义为三阴性MPN。随着二代测序技术的发展,三阴性MPN的... 骨髓增殖性肿瘤(MPN)是髓系细胞过度增生引起的血液系统疾病。大多数MPN患者中可检出Janus激酶(JAK)2、血小板生成素受体基因及钙网蛋白基因突变,未检出上述3种基因突变MPN患者被定义为三阴性MPN。随着二代测序技术的发展,三阴性MPN的多种非驱动基因突变被检出,如10-11易位甲基胞嘧啶双加氧酶2、异柠檬酸脱氢酶1/2、Zeste基因增强子同源物2、DNA甲基转移酶3A、附加性梳样结构1、Casitas B细胞淋巴瘤、淋巴细胞衔接蛋白等。不同基因突变MPN的临床特点存在一定异质性,可用于指导疾病治疗及评估患者预后。MPN的传统治疗药物有羟基脲、干扰素等,随着分子研究的不断突破,JAK-信号转导及转录活化因子通路抑制剂逐渐在临床广泛应用,未来还有望研发出一些新的靶向药物。 展开更多
关键词 骨髓增殖性肿瘤 基因突变 干扰素 羟基脲 Janus激酶抑制剂
暂未订购
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia
16
作者 Xiao Huang Tingting Ma +5 位作者 Yongmei Zhu Bo Jiao Shanhe Yu Kankan Wang Jian-Qing Mi Ruibao Ren 《Frontiers of Medicine》 SCIE CSCD 2022年第3期403-415,共13页
The morbidity and mortality of myeloproliferative neoplasms(MPNs)are primarily caused by arterial and venous complications,progression to myelofibrosis,and transformation to acute leukemia.However,identifying molecula... The morbidity and mortality of myeloproliferative neoplasms(MPNs)are primarily caused by arterial and venous complications,progression to myelofibrosis,and transformation to acute leukemia.However,identifying molecular-based biomarkers for risk stratification of patients with MPNs remains a challenge.We have previously shown that interferon regulatory factor-8(IRF8)and IRF4 serve as tumor suppressors in myeloid cells.In this study,we evaluated the expression of IRF4 and IRF8 and the JAK2V617F mutant allele burden in patients with MPNs.Patients with decreased IRF4 expression were correlated with a more developed MPN phenotype in myelofibrosis(MF)and secondary AML(sAML)transformed from MPNs versus essential thrombocythemia(ET).Negative correlations between the JAK2V617F allele burden and the expression of IRF8(P<0.05)and IRF4(P<0.001)and between white blood cell(WBC)count and IRF4 expression(P<0.05)were found in ET patients.IRF8 expression was negatively correlated with the JAK2V617F allele burden(P<0.05)in polycythemia vera patients.Complete response(CR),partial response(PR),and no response(NR)were observed in 67.5%,10%,and 22.5%of ET patients treated with hydroxyurea(HU),respectively,in 12 months.At 3 months,patients in the CR group showed high IRF4 and IRF8 expression compared with patients in the PR and NR groups.In the 12-month therapy period,low IRF4 and IRF8 expression were independently associated with the unfavorable response to HU and high WBC count.Our data indicate that the expression of IRF4 and IRF8 was associated with the MPN phenotype,which may serve as biomarkers for the response to HU in ET. 展开更多
关键词 myeloproliferative neoplasms IRF4 IRF8 hydroxyurea essential thrombocythemia
暂未订购
重组腺相关病毒感染细胞后目的蛋白表达水平检测方法的建立及验证
17
作者 裴德宁 闫书美 +3 位作者 史新昌 胡倩 周勇 刘宾 《中国生物制品学杂志》 CAS CSCD 2024年第6期646-650,655,共6页
目的建立重组腺相关病毒(recombinant adeno-associated virus,rAAV)感染细胞后目的蛋白表达水平的检测方法,并进行方法验证,以期用于rAAV9生产过程中不同阶段产物的质量监控。方法将rAAV9供试品用感染增强剂Envirus-AAV处理后,感染经... 目的建立重组腺相关病毒(recombinant adeno-associated virus,rAAV)感染细胞后目的蛋白表达水平的检测方法,并进行方法验证,以期用于rAAV9生产过程中不同阶段产物的质量监控。方法将rAAV9供试品用感染增强剂Envirus-AAV处理后,感染经羟基脲(hydroxyurea,HU)作用的人脑星形胶质母细胞瘤细胞U87-MG,以rAAV9参考品为标准,采用ELISA法检测细胞中目的蛋白戊二酰辅酶A脱氢酶(glutaryl-CoA dehydrogenase,GCDH)的表达水平,并验证方法的专属性、准确性、精密性、线性范围、定量限及耐用性。采用建立的方法检测8批rAAV9供试品。结果供试品缓冲液的A_(450)-A_(630)为0.3,略低于蛋白定量四参数标准曲线最低稀释点(1 ng/mL);150%、100%、50%理论相对效价水平样品平均回收率均在100.0%~107.3%范围内;同1名实验员重复3次及不同实验员检测3个理论相对效价水平样品的目的蛋白表达水平RSD均<25%;rAAV9供试品在50%~150%理论相对效价水平范围内,与相应的目的蛋白表达水平呈良好的线性关系,直线回归方程为y=1.077 x-0.022,R~2为0.984;方法的定量限为0.59,即6.0×10^(12)vg/mL;U87-MG细胞用HU孵育不同时间(18、21、24 h)、细胞培养上清液于不同条件(室温放置0.5 h、-60℃以下放置12 h、-60℃以下放置24 h)保存后,目的蛋白表达水平RSD均<25%。1~8批rAAV9供试品目的蛋白表达水平分别为111%、121%、72%、65%、86%、75%、102%、91%。结论建立的rAAV感染细胞后目的蛋白表达水平检测方法具有良好的专属性、准确性、精密性及耐用性,可用于rAAV9生产过程中不同阶段产物的质量监控。 展开更多
关键词 重组腺相关病毒 人脑星形胶质母细胞瘤细胞 目的蛋白 羟基脲 感染增强剂 酶联免疫吸附试验
原文传递
羟基脲联合沙利度胺治疗JAK2V617F阳性骨髓增殖性肿瘤的临床疗效及安全性评价
18
作者 宋腾飞 王晓晶 马丽丽 《肿瘤药学》 CAS 2024年第4期468-473,共6页
目的研究羟基脲联合沙利度胺治疗JAK2V617F阳性骨髓增殖性肿瘤(MPN)的临床疗效及安全性评价。方法采用前瞻性分析方法,选取2020年1月—2023年1月在我院门诊或住院接受荧光定量PCR检测确定为JAK2V617F阳性MPN的患者80例为研究对象,根据... 目的研究羟基脲联合沙利度胺治疗JAK2V617F阳性骨髓增殖性肿瘤(MPN)的临床疗效及安全性评价。方法采用前瞻性分析方法,选取2020年1月—2023年1月在我院门诊或住院接受荧光定量PCR检测确定为JAK2V617F阳性MPN的患者80例为研究对象,根据治疗方案分为观察组(40例)与对照组(40例)。对照组采用沙利度胺治疗,观察组患者采用羟基脲联合沙利度胺治疗。统计并比较两组患者治疗前及治疗后6、12个月的临床疗效,JAK2V617F突变负荷,血小板(PLT)、白细胞(WBC)、血红蛋白(HGB)、红细胞比容(HCT)水平,骨髓纤维化程度,骨髓形态学及用药安全性。结果治疗后,观察组总有效率显著高于对照组(P<0.05);治疗后6、12个月,两组患者JAK2V617F突变负荷,PLT、HGB水平,MPN-10评分,MF分级均显著低于治疗前,且观察组均显著低于对照组(P<0.05);而WBC、HCT水平无明显变化(P>0.05);观察组患者骨髓细胞异常增生发生率明显低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论羟基脲联合沙利度胺治疗JAK2V617F阳性MPN患者具有显著效果,可有效改善临床症状,降低JAK2V617F阳性突变负荷,逆转骨髓纤维化水平。 展开更多
关键词 骨髓增殖性肿瘤 JAK2V617F阳性 羟基脲 沙利度胺
暂未订购
羟基脲引起骨髓抑制致丹毒并伴疑似药物热1例
19
作者 李晓晔 段文博 +2 位作者 谢雅君 耿帅 史宁 《创伤与急危重病医学》 2024年第4期255-258,共4页
1临床资料患者男性,68岁,2023年9月4日主诉“间断头晕半年”入院。既往有“右侧下肢静脉曲张;高血压病”病史,否认血液病病史。入院查体:体温36.5℃;脉搏68次/min;血压142/71 mmHg(1 mmHg=0.133 kPa);经皮血氧饱和度91%~95%(低流量吸氧1... 1临床资料患者男性,68岁,2023年9月4日主诉“间断头晕半年”入院。既往有“右侧下肢静脉曲张;高血压病”病史,否认血液病病史。入院查体:体温36.5℃;脉搏68次/min;血压142/71 mmHg(1 mmHg=0.133 kPa);经皮血氧饱和度91%~95%(低流量吸氧1 L/min);口唇及双手末端颜色发绀,双肺呼吸音粗,未闻及干湿性啰音。右侧上肢脉搏较左侧差。右侧下肢静脉曲张,小腿远端有皮肤色素沉着。 展开更多
关键词 羟基脲 真性红细胞增多症 骨髓抑制 药物热
暂未订购
口服羟基脲致纵向黑甲及皮肤舌黏膜色素沉着1例
20
作者 白亚菲 《实用皮肤病学杂志》 2024年第6期380-381,386,共3页
报告羟基脲致甲板、口周及舌黏膜色素沉着1例。患者女,66岁,手足指(趾)甲进行性变黑1年余。3年前因出现皮肤瘙痒、头晕乏力及指端紫绀伴疼痛,于外院行相关检查后,诊断为真性红细胞增多症,给予羟基脲1.5 g,每日2次口服,治疗至今。皮肤科... 报告羟基脲致甲板、口周及舌黏膜色素沉着1例。患者女,66岁,手足指(趾)甲进行性变黑1年余。3年前因出现皮肤瘙痒、头晕乏力及指端紫绀伴疼痛,于外院行相关检查后,诊断为真性红细胞增多症,给予羟基脲1.5 g,每日2次口服,治疗至今。皮肤科检查:双手及右足多个指(趾)甲出现纵向线状或条带状黑色改变,部分扩展至全甲,呈黑灰色或黑褐色改变。口周弥漫性轻度色素沉着,舌背黏膜2处小米粒样雀斑样黑色斑点。口腔内齿龈及颊黏膜未见异常。结合患者病史及临床表现,诊断:羟基脲所致纵向黑甲及皮肤黏膜色素沉着。停止服用羟基脲后,色素沉着病情有缓解。 展开更多
关键词 纵向黑甲 色素沉着 羟基脲
暂未订购
上一页 1 2 9 下一页 到第
使用帮助 返回顶部